Stock Research: GlaxoSmithKline Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

GlaxoSmithKline Pharmaceuticals

BSE:500660 INE159A01016
65
  • Value
    83
  • Growth
    79
  • Safety
    Safety
    15
  • Combined
    70
  • Sentiment
    34
  • 360° View
    360° View
    65
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company manufacturing, distributing, and trading in pharmaceuticals. The company operates in vaccines, specialty, and general medicine, with popular brands including Augmentin, Calpol, Shingrix, and Nucala. It operates primarily in India. In the last fiscal year, the company had 3113 employees, a market cap of $6242 millions, profits of $262 millions, and revenue of $439 millions.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 65 (better than 65% compared with alternatives), overall professional sentiment and financial characteristics for the stock GlaxoSmithKline Pharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for GlaxoSmithKline Pharmaceuticals. The consolidated Growth Rank has a good rank of 79, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 79% of competitors in the same industry. In addition, the consolidated Safety Rank has a safer rank of 83 which means that the company has a financing structure that is safer than 83% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the consolidated Value Rank has a less desirable rank of 15 which means that the share price of GlaxoSmithKline Pharmaceuticals is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is higher than for 85% of alternative stocks in the same industry. The consolidated Sentiment Rank also has a low rank of 34, which means that professional investors are more pessimistic about the stock than for 66% of alternative investment opportunities. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
15 13 17 29
Growth
79 87 25 31
Safety
Safety
83 77 79 65
Sentiment
34 77 32 1
360° View
360° View
65 79 16 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
52 74 43 13
Opinions Change
31 94 50 50
Pro Holdings
n/a 54 77 49
Market Pulse
17 46 7 5
Sentiment
34 77 32 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
15 13 17 29
Growth
79 87 25 31
Safety Safety
83 77 79 65
Combined
70 77 19 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
17 19 12 20
Price vs. Earnings (P/E)
3 1 12 16
Price vs. Book (P/B)
7 5 10 7
Dividend Yield
67 56 74 76
Value
15 13 17 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
62 44 28 10
Profit Growth
45 92 45 88
Capital Growth
87 65 25 7
Stock Returns
61 77 71 53
Growth
79 87 25 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
93 92 90 82
Refinancing
24 18 26 22
Liquidity
94 92 92 80
Safety Safety
83 77 79 65

Similar Stocks

Discover high‑ranked alternatives to GlaxoSmithKline Pharmaceuticals and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.